Skip to Content


In the US, Abciximab (abciximab systemic) is a member of the drug class glycoprotein platelet inhibitors and is used to treat High Risk Percutaneous Transluminal Angioplasty.

US matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Categories

Biological response modifier, BRM

Monoclonal antibody

Antiplatelet agent: Glycoprotein IIb/IIIa-receptor antagonist

Chemical Name

Immunoglobulin G1, anti-(human integrin αIIbβ3) Fab fragment (human-mouse monoclonal c7E3 clone p7E3VHhCγ₁ γ1-chain), disulfide with human-mouse monoclonal c7E3 clone p7E3VκhCκ kappa-chain (WHO )

Foreign Names

  • Abciximabum (Latin)
  • Abciximab (German)
  • Abciximab (French)
  • Abciximab (Spanish)

Generic Names

Brand Names

  • Clotinab
    Cardiopharm, Chile; Isu Abxis, Thailand
  • Reopro
    2care4, Norway; Centocor, Czech Republic; Eli Lilly, Argentina; Eli Lilly, Australia; Eli Lilly, Belgium; Eli Lilly, Brazil; Eli Lilly, Ireland; Eli Lilly, Mexico; Eli Lilly, Malaysia; Eli Lilly and Company, United Kingdom; Eli Lilly de Chile, Chile; Janssen, Hong Kong; Janssen, Norway; Janssen Biologics, Netherlands; Janssen-Cilag, Poland; Lilly, Spain; Lilly, Finland; Lilly, Italy; Lilly, New Zealand; Lilly, Portugal; Lilly, Taiwan; Lilly, South Africa; Lilly-Pharmaserve, Greece
  • ReoPro
    Centocor, Bulgaria; Eli Lilly, Switzerland; Eureco-Pharma, Netherlands; Euro Registratie, Netherlands; Fisher Farma, Netherlands; Janssen, Iceland; Janssen Biologics, Austria; Lilly, Canada; Lilly, Germany; Lilly, Sweden; Orifarm, Netherlands
  • Réopro
    Lilly, France


BANBritish Approved Name
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.